Calciphylaxis - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights

• The calciphylaxis market is projected to maintain a steady Compound Annual Growth Rate (CAGR) from 2025 to 2034. This growth is driven by increasing disease recognition, a growing end-stage renal disease (ESRD) population, increased clinical awareness, increased dialysis use, and ongoing research into targeted therapeutic options for this rare but serious condition.
• As per secondary research, the incidence of calciphylaxis among dialysis patients is estimated between 0.04% and 4%, with trends indicating an upward trajectory in recent years.
• Calciphylaxis affects an estimated 1-35 per 10,000 dialysis patients annually, though cases are likely underreported due to limited awareness. Key risk factors include hemodialysis, female sex, obesity, diabetes, electrolyte imbalances, autoimmune diseases, hypoalbuminemia, elevated alkaline phosphatase, and use of medications like warfarin, calcium, vitamin D, iron, and PTH analogs.
• Calciphylaxis currently has no approved treatments or standardized care protocols. Management relies on IV sodium thiosulfate, wound care, and metabolic correction, but efficacy is uncertain. Avoiding pro-calcific drugs and using adjuncts like intensified dialysis offer limited benefit. Prognosis remains poor, underscoring the need for targeted disease modifying therapies.
• The calciphylaxis drug pipeline is limited, with INZ-701 from Inozyme Pharma emerging as a leading investigational therapy, having completed its Phase I clinical trial.
• In July 2025, BioMarin completed its acquisition of Inozyme Pharma for USD 4.00 per share in an all-cash deal valued at approximately USD 270 million. The acquisition expanded BioMarin’s enzyme therapy portfolio with INZ-701, developing for 3 rare and progressive genetic disease affecting blood vessels, soft tissue, and bone.

The comprehensive report titled “Calciphylaxis - Market Insights, Epidemiology, and Market Forecast - 2034” offers a detailed analysis of Calciphylaxis. The report presents historical and projected epidemiological data covering total incident cases of calciphylaxis, gender-specific cases of calciphylaxis, age-specific cases of calciphylaxis, and treated cases of calciphylaxis. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in calciphylaxis. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Calciphylaxis Overview

Calciphylaxis is a rare, life-threatening disease characterized by widespread calcification of small blood vessels, leading to reduced blood flow, tissue ischemia, and subsequent skin and soft tissue necrosis. It most commonly occurs in individuals with advanced kidney disease, especially those on dialysis, although cases have been reported in people without kidney failure.

Patients typically present with extremely painful, purplish-red or net-like skin lesions, most often on areas containing more fat such as the thighs, abdomen, and buttocks. As the disease progresses, these lesions can ulcerate, develop black-brown necrotic crusts, and often become infected, significantly increasing the risk of sepsis and mortality. The condition’s prognosis is poor, with high rates of morbidity and mortality, primarily due to non-healing wounds and subsequent infections.

Calciphylaxis Diagnosis and Treatment Algorithm

Diagnosing calciphylaxis requires strong clinical suspicion, with confirmation typically made via skin biopsy revealing medial calcification of dermal arterioles, fibrointimal hyperplasia, microthrombi, or tissue necrosis. However, biopsies carry risks such as ulceration or infection, especially in early nodular lesions, prompting some clinicians to initiate treatment based on clinical judgment alone. A diagnostic workup includes metabolic panels, liver function, coagulation studies, and albumin levels, with hypercoagulable screening considered in select cases. Experimental methods like nuclear bone scans and fetuin-A level assessment may aid in diagnosis.

Management of calciphylaxis focuses on correcting bone-mineral imbalances, discontinuing high-risk medications, and providing wound care and symptom relief. Key steps include avoiding hypercalcemia, maintaining phosphorus levels below 5.5 mg/dL, and optimizing dialysis. Calcium-based phosphate binders should be replaced with non-calcium alternatives, and high-calcium dialysate baths avoided. Cinacalcet is preferred for secondary hyperparathyroidism, with etelcalcetide as an alternative.

Warfarin should be discontinued due to its association with calciphylaxis, and vitamin K supplementation is under investigation. Sodium thiosulfate, used off-label, has shown promising results in improving skin lesions, though its mechanism is not fully understood and may involve non-calcium-binding pathways. Debridement is often necessary, and hyperbaric oxygen therapy may support healing. Some improvement has been observed after kidney transplantation, but post-transplant cases can still occur, partly due to immunosuppressive therapy.

Calciphylaxis Epidemiology

The epidemiology section of the calciphylaxis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the incidence of calciphylaxis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• According to the study by Marin et al. (2023), the incidence of calciphylaxis among patients undergoing maintenance hemodialysis is estimated at 3.49 per 1,000 patient-years.
• As per the study by Altman et al. (2019), calciphylaxis has an annual incidence of 35 cases per 10,000 patients in the United States.
• The estimated annual incidence of calciphylaxis ranges from 1 to 35 cases per 10,000 dialysis patients worldwide.
• According to the study by Chinnadurai et al. (2021) in the UK, calciphylaxis prevalence among dialysis patients ranges between 1% and 4%, with an estimated annual incidence of approximately 0.04%. The condition is associated with a high mortality rate, reaching up to 60% annually.
• The epidemiology of calciphylaxis is expected to change during the forecast period (2025-2034).

Calciphylaxis Market Outlook

The calciphylaxis therapeutics market is projected to grow steadily during the forecast period (2025-2034), driven by a rising incidence among hemodialysis patients along with increasing awareness, technological advancements, and the anticipated launch of novel therapies targeting this high-risk, underserved population.

With ongoing research and continued commitment, there is growing optimism for more effective treatments and potentially a cure for calciphylaxis, a life-threatening and underserved condition. According to the publisher, the calciphylaxis market in the 7MM is expected to change significantly during the forecast period 2025-2034.

Calciphylaxis Drug Chapters

Emerging Calciphylaxis Drugs

The calciphylaxis market is expected to evolve gradually, driven by the limited number of emerging therapies currently in development. Key players such as INZ-701 by Inozyme Pharma, among others are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex condition.

INZ-701: Inozyme Pharma

INZ-701 is an ENPP1 enzyme replacement therapy (ERT) given as an injection under the skin (subcutaneous injection) that is designed to increase PPi and adenosine in the body to help improve or prevent symptoms of calciphylaxis.

In October 2024, Inozyme announced positive interim results from its Phase I SEAPORT 1 trial of INZ-701 in patients with ESKD on hemodialysis. INZ-701 significantly increased PPi levels and was well tolerated. Company plans to initiate a registrational trial in calciphylaxis in 2025 subject to regulatory alignment and sufficient funding.

Calciphylaxis Market Segmentation

The ‘Calciphylaxis - Market Insights, Epidemiology, and Market Forecast - 2034’ report provides a detailed outlook of the current and future calciphylaxis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Calciphylaxis Market Size by Countries

The calciphylaxis market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) calciphylaxis market, primarily attributed to the country’s higher incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential introduction of new products.

Calciphylaxis Drugs Uptake

This section focuses on the sales uptake of potential calciphylaxis drugs that have recently been launched or are anticipated to be launched in the calciphylaxis market between 2020 and 2034. It estimates the market penetration of calciphylaxis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the calciphylaxis market.

The emerging calciphylaxis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the calciphylaxis market.

Calciphylaxis Market Access and Reimbursement

The ‘Calciphylaxis- Market Insights, Epidemiology, and Market Forecast - 2034’ report provides a descriptive overview of the market access and reimbursement scenario of calciphylaxis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current calciphylaxis market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the calciphylaxis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or calciphylaxis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the calciphylaxis unmet needs.

Calciphylaxis: KOL Insights

The analysts connected with 25+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as University of Manchester, UK, Harvard University, US, RWTH Aachen University Hospital, Germany, University of Barcelona, Spain, Nantes University Hospital, France, and University of Tokyo, Japan, among others.
“Due to the potential involvement of bone-mineral imbalances in calciphylaxis, it is important to prevent hypercalcemia and keep serum phosphorus levels below 5.5 mg/dL. At the very least, patients should meet established dialysis adequacy standards, and dialysis frequency may be increased when needed to enhance the removal of uremic toxins and better regulate bone-mineral parameters.”
“Despite its high mortality rate, calciphylaxis lacks both definitive diagnostic tests and approved treatments. However, researchers have identified certain risk factors linked to poorer outcomes, including cardiovascular disease, diabetes mellitus, and the use of warfarin. These factors may contribute to increased mortality due to their association with widespread vascular calcification.
“Calciphylaxis can occur in individuals with chronic kidney disease (CKD) even when their serum calcium and phosphate levels are within normal ranges. Notably, variations in the vitamin D receptor gene have also been linked to the development of this condition. Additionally, cases have been documented where calciphylaxis presents alongside nephrogenic fibrosing dermopathy in patients undergoing maintenance dialysis.”

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the calciphylaxis Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Calciphylaxis Pipeline Development Activities

The report offers an analysis of therapeutic candidates and examines companies involved in developing targeted therapeutics for calciphylaxis. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging calciphylaxis therapies.

Calciphylaxis Report Insights

• Calciphylaxis Patient Population
• Therapeutic Approaches
• Calciphylaxis Pipeline Analysis
• Calciphylaxis Market Size and Trends
• Calciphylaxis Market Opportunities
• Impact of Upcoming Therapies

Calciphylaxis Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Calciphylaxis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Calciphylaxis Market
• Calciphylaxis Drugs Uptake

Calciphylaxis Report Assessment

• Calciphylaxis Current Treatment Practices
• Unmet Needs
• Calciphylaxis Pipeline Product Profiles
• Calciphylaxis Market Attractiveness

Key Questions

• How common is calciphylaxis?
• What are the key findings of calciphylaxis epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for calciphylaxis?
• What are the disease risk, burden, and unmet needs of calciphylaxis?
• At what CAGR is the calciphylaxis market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the calciphylaxis market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of calciphylaxis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of calciphylaxis?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the calciphylaxis Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.